BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.64%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.56B
AUM Growth
+$6.56B
(+0.3%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-3.2%
Top 10 Holdings %
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14
Top Buys
| 1 |
DexCom
DXCM
|
$42.5M |
| 2 |
Cooper Companies
COO
|
$31.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$17.8M |
| 4 |
SI-BONE Inc
SIBN
|
$16.6M |
| 5 |
Steris
STE
|
$16.5M |
Top Sells
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$114M |
| 2 |
Intuitive Surgical
ISRG
|
$59.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$51.7M |
| 4 |
Evolent Health
EVH
|
$29.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$28.3M |
Sector Composition
| 1 | Healthcare | 99.12% |
| 2 | Industrials | 0.77% |
| 3 | Technology | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $360M | 5.49% | 8,299,514 -414,473 | -5% | -$18M |
|
2
argenx
ARGX
$43.6B
| $319M | 4.87% | 811,016 -58,192 | -7% | -$22.9M |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $284M | 4.32% | 2,055,874 -374,626 | -15% | -$51.7M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $280M | 4.26% | 668,750 -67,640 | -9% | -$28.3M |
|
|
5
Intuitive Surgical
ISRG
$170B
| $272M | 4.15% | 682,186 -149,855 | -18% | -$59.8M |
|
6
Boston Scientific
BSX
$156B
| $216M | 3.29% | 3,148,676 -21,927 | -0.7% | -$1.5M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $195M | 2.98% | 2,819,482 -246,918 | -8% | -$17.1M |
|
8
Moderna
MRNA
$9.37B
| $182M | 2.78% | 1,711,089 -197,331 | -10% | -$21M |
|
|
9
DexCom
DXCM
$29.5B
| $169M | 2.58% | 1,221,197 +306,604 | +34% | +$42.5M |
|
10
Revolution Medicines
RVMD
$7.1B
| $164M | 2.49% | 5,073,600 -17,400 | -0.3% | -$561K |
|
11
Abbott
ABT
$231B
| $163M | 2.49% | 1,434,183 -101,473 | -7% | -$11.5M |
|
12
Stryker
SYK
$150B
| $161M | 2.45% | 449,340 -16,384 | -4% | -$5.86M |
|
13
MacroGenics
MGNX
$112M
| $147M | 2.24% | 9,965,862 +12,549 | +0.1% | +$185K |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $137M | 2.09% | 918,284 +32,966 | +4% | +$4.93M |
|
15
Incyte
INCY
$16.5B
| $123M | 1.87% | 2,153,388 -3,331 | -0.2% | -$190K |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $117M | 1.79% | 2,796,615 +380,319 | +16% | +$16M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $117M | 1.79% | 4,006,000 -5,000 | -0.1% | -$146K |
|
18
Edwards Lifesciences
EW
$47.8B
| $105M | 1.61% | 1,103,136 +84,138 | +8% | +$8.04M |
|
19
Becton Dickinson
BDX
$55.3B
| $103M | 1.57% | 415,700 +27,632 | +7% | +$6.84M |
|
20
Arvinas
ARVN
$568M
| $98.7M | 1.51% | 2,390,800 -116,931 | -5% | -$4.83M |
|
21
Medtronic
MDT
$119B
| $87.8M | 1.34% | 1,007,000 +36,228 | +4% | +$3.16M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $83.7M | 1.28% | 4,465,544 +952,193 | +27% | +$17.8M |
|
23
Exact Sciences
EXAS
$8.98B
| $78.6M | 1.2% | 1,138,526 +90,740 | +9% | +$6.27M |
|
24
UnitedHealth
UNH
$281B
| $73.6M | 1.12% | 148,719 +10,567 | +8% | +$5.23M |
|
25
Tandem Diabetes Care
TNDM
$845M
| $71.9M | 1.1% | 2,031,888 +39,571 | +2% | +$1.4M |
|